Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
六月清晨搅
发表于 5 天前
122
0
0
On December 18th, the National Medical Products Administration of China approved Eli Lilly and Company's (hereinafter referred to as "Eli Lilly") Alzheimer's disease therapy, JiNengda&Co; reg; (Donaimab injection, intravenous infusion once every four weeks) is used to treat mild cognitive impairment and Alzheimer's disease mild dementia in adults caused by Alzheimer's disease.
It is reported that Ji Nengda& reg; It is the only targeted amyloid therapy with evidence supporting discontinuation after clearing amyloid plaques, which can help patients reduce treatment burden by reducing infusion frequency and treatment costs. After the United States, Japan, and the United Kingdom, China has approved the use of Minolta; reg; Another major market for listing.
It is estimated that 32 million people worldwide suffer from Alzheimer's disease dementia and have confirmed pathological changes in amyloid protein. There are currently nearly 9.83 million Alzheimer's disease patients in China. Moreover, the ranking of total deaths caused by dementia in China has risen from the tenth place in 1990 to the fifth place in 2019. At the same time, Alzheimer's disease also brings a heavy economic burden to families and society. Research shows that in 2015, the average annual cost of Alzheimer's disease patients in China reached 1.1 trillion yuan, accounting for about 1.47% of the gross domestic product (GDP). It is estimated that the socio-economic cost of Alzheimer's disease patients in China will reach 3.2 trillion yuan by 2030 and 11.9 trillion yuan by 2050.
Today's approval marks an important milestone in our commitment to changing the treatment of Alzheimer's disease in China. Due to the accelerated aging of the population, Alzheimer's disease has become a significant medical burden in China. We hope to achieve this goal, "said De Helan, President and General Manager of Eli Lilly China; Providing patients with opportunities for early intervention can help slow down the progression of this serious disease
Wang Li, Senior Vice President of Eli Lilly Global and Head of Eli Lilly China's Center for Drug Development and Medical Affairs, said, "Just five months after obtaining the world's first market approval, JiNengda® As a Class 1 innovative drug, it has obtained market approval in China, which fully reflects the support of regulatory authorities for the priority review and approval of breakthrough therapeutic drugs, and also demonstrates Lilly's commitment to accelerating the provision of breakthrough therapies for Chinese patients
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Wal Mart stores in China are fully launched in Meituan
- Most popular Chinese concept stocks in the US stock market have risen, while the Nasdaq China Golden Dragon Index has risen by nearly 2%
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Yum Brands China: The number of domestic stores with 30 Pizzahut products has reached 3606
- Eli Lilly's Alzheimer's disease treatment with donentinumab injection approved
- BeiGene ADC's new cancer drug BG-C137 has been clinically approved for the first time in China
- Popular Chinese concept stocks fluctuated on Friday, with the Nasdaq China Golden Dragon Index closing up 0.53%
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【ビットコインが飛び込む!32万人超の爆倉】データによると、過去24時間で世界には32万7000人以上の爆倉があり、爆倉の総額は10億ドルを超えた。
- 断翅小蝶腥
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
南方財経12月20日電によると、元テスラ製造副総裁の宋鋼氏が将来像集積サプライチェーン高級副総裁に就任する。現在、ビジョンの企業OAにはすでに個人情報が表示されており、関連直属の上司はビジョンテクノロジー ...
- 内托体头
- 3 天前
- 支持
- 反对
- 回复
- 收藏